Molecular genetic abnormalities in myeloid/lymphoid neoplasms associated with eosinophilia
| Disease . | Presentation . | Genetics . | Treatment . |
|---|---|---|---|
| PDGFRA | Eosinophilia | Cryptic deletion at 4q12 | Respond to TKI |
| ↑Serum tryptase | FIP1L1-PDGFRA, at least 66 other partners | ||
| ↑Marrow mast cells | |||
| PDGFRB | Eosinophilia | t(5;12)(q32;p13.2) ETV6-PDGFRB, at least 25 other partners | Respond to TKI |
| Monocytosis mimicking CMML | |||
| FGFR1 | Eosinophilia | Translocations of 8p11.2 | Poor prognosis; do not respond to TKI |
| Often presents with T-ALL or AML | FGFR1-various partners | ||
| PCM1-JAK2 | Eosinophilia | t(8;9)(p22;p24.1) PCM1-JAK2 | May respond to JAK2 inhibitors |
| Rarely presents with T-LBL or B-ALL | |||
| Bone marrow shows left-shifted erythroid predominance and lymphoid aggregates |
| Disease . | Presentation . | Genetics . | Treatment . |
|---|---|---|---|
| PDGFRA | Eosinophilia | Cryptic deletion at 4q12 | Respond to TKI |
| ↑Serum tryptase | FIP1L1-PDGFRA, at least 66 other partners | ||
| ↑Marrow mast cells | |||
| PDGFRB | Eosinophilia | t(5;12)(q32;p13.2) ETV6-PDGFRB, at least 25 other partners | Respond to TKI |
| Monocytosis mimicking CMML | |||
| FGFR1 | Eosinophilia | Translocations of 8p11.2 | Poor prognosis; do not respond to TKI |
| Often presents with T-ALL or AML | FGFR1-various partners | ||
| PCM1-JAK2 | Eosinophilia | t(8;9)(p22;p24.1) PCM1-JAK2 | May respond to JAK2 inhibitors |
| Rarely presents with T-LBL or B-ALL | |||
| Bone marrow shows left-shifted erythroid predominance and lymphoid aggregates |
↑, Increased.